Abstract Library

#3043 Angiogenetic Markers as Prognostic Predictors in Neuroendocrine Neoplasms

Introduction: Neoangiogenesis is crucial for NEN development and metastatization.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Puliani G

Authors: Puliani G, Feola T, Sesti F, Sciarra F, Campolo F,

Keywords: biomarkers, prognosis,

#2834 Tumor-Promoting Effects of the Transcriptional Regulator CUX1 in PanNET

Introduction: Previously, we identified CUX1 as mediator of metastatic behaviour and poor differentiation in human insulinomas. CUX1 mediated tumor-promoting functions via enhancing proliferation, resistance to apoptosis and angiogenesis in-vitro and in-vivo.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Weißbach J

Authors: Weißbach J, Schmitz R, Haybäck J, Perren A, Blank A,

Keywords: CUX1, RIP1Tag2, DAPK1, Apoptosis, Tumor Progression,

#2742 Anti-Tumor Effects of Semaphorin 4D Blockade Unravel a Novel Pro-Invasive Mechanism of Vascular Targeting Agents

Introduction: One of the main consequences of inhibition of neovessel growth produced by angiogenesis inhibitors is increased intratumor hypoxia. Growing evidence indicates that tumor cells escape from this hypoxic environment to better nourished locations, presenting hypoxia as a positive stimulus for invasion. Particularly, anti-VEGF/R therapies produce hypoxia-induced invasion and metastasis in a spontaneous mouse model of pancreatic neuroendocrine cancer, RIP1-Tag2.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Casanovas O

Authors: Zuazo-Gaztelu I, Pàez-Ribes M, Carrasco P, Martín-Mitjana L, Sallaberry J,

Keywords: Antiangiogenic therapies, Semaphorin 4D, Mouse models of NETs, Invasion and metastasis,

#2685 Apatinib Inhibits Tumor Growth and Angiogenesis in PNET Models

Introduction: Angiogenesis has a pivotal role in the growth and metastasis of pancreatic neuroendocrine tumors (PNETs). Apatinib inhibits angiogenesis as a highly selective KDR inhibitor and has been used to treat advanced gastric cancer and malignancies in clinical settings. However, the efficacy of apatinib in PNETs remains unclear.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Wang z

Authors: Wu S, Zhou J, Guo J, Hua Z, Li J,

Keywords: Pancreatic neuroendocrine tumors, angiogenesis, KDR, apatinib, liver metastasis,

#2265 Activity of Bevacizumab in Neuroendocrine Neoplasms

Introduction: The combination of the anti-VEGF antibody bevacizumab (BEV) with a multitude of other antineoplastic substances has shown promising activity in neuroendocrine neoplasms (NEN). However, data proving the superiority of BEV-containing vs. BEV-free protocols are lacking.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Apostolidis L

Authors: Fejzibegovic N, Jäger D, Winkler E, Apostolidis L,

Keywords: neuroendocrine neoplasm, targeted therapy, bevacizumab, antiangiogenesis,